Atea Pharmaceuticals Inc
AVIR
Company Profile
Business description
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
Contact
225 Franklin Street
Suite 2100
BostonMA02110
USAT: +1 857 284-8891
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
56
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,287.90 | 84.00 | 1.02% |
| CAC 40 | 7,548.82 | 24.94 | -0.33% |
| DAX 40 | 22,374.37 | 102.70 | 0.46% |
| Dow JONES (US) | 40,338.49 | 110.90 | 0.28% |
| FTSE 100 | 8,446.98 | 29.64 | 0.35% |
| HKSE | 22,008.11 | 36.15 | 0.16% |
| NASDAQ | 17,262.23 | 103.91 | -0.60% |
| Nikkei 225 | 35,839.99 | 134.25 | 0.38% |
| NZX 50 Index | 12,025.45 | 73.44 | -0.61% |
| S&P 500 | 5,510.44 | 18.31 | -0.33% |
| S&P/ASX 200 | 8,070.60 | 73.50 | 0.92% |
| SSE Composite Index | 3,286.65 | 1.76 | -0.05% |